Clinical application of targeted and genome-wide technologies: Can we predict treatment responses in chronic lymphocytic leukemia?

Personalized Medicine

Volumn 10, Issue 4, 2013, Pages 361-376

  Alsolami, Reem ^a,b   Knight, Samantha Jl ^a,c   Schuh, Anna ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

chronic lymphocytic leukemia; genome wide technologies; massively parallel sequencing; next generation technology; predictive biomarker; prognostic biomarker; SNP microarray

Indexed keywords

BIRC3 PROTEIN; CYCLOPHOSPHAMIDE; EXPORTIN 1; FLUDARABINE; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; PROTEIN P53; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MOSAICISM; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TRISOMY 12;

EID: 84878900455     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.33     Document Type: Review

References (121)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7), 2292-2302 (2002).
2. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87(1), 89-99 (2012).
3. Sullivan C, Peng C, Chen Y, Li D, Li S. Targeted therapy of chronic myeloid leukemia. Biochem. Pharmacol. 80(5), 584-591 (2010).
4. Tallman MS, Brenner B, Serna Jde L et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk. Res. 29(3), 347-351 (2005).
5. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). National Cancer Institute, MD, USA (2012).
6. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 10(1), 37-50 (2010).
7. Clifford R, Schuh A. State-of-the-art management of patients suffering from chronic lymphocytic leukemia. Clin. Med. Insights Oncol. 6, 165-178 (2012).
8. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
9. Robak T, Dmoszynska A, Solal-Celigny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1756-1765 (2010).
10. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000).
11. Dohner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 11(Suppl. 2), S19-S24 (1997).
12. Klein U, Lia M, Crespo M et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17(1), 28-40 (2010).
13. Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28(29), 4473-4479 (2010).
14. Stankovic T, Kidd AM, Sutcliffe A et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 62(2), 334-345 (1998).
15. Puente XS, Pinyol M, Quesada V et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475(7354), 101-105 (2011).
16. Schuh A, Becq J, Humphray S et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120(20), 4191-4196 (2012).
17. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat. Rev. Clin. Oncol. 8(1), 38-47 (2011).
18. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer 44(7), 946-953 (2008).
19. Zenz T, Frohling S, Mertens D, Dohner H, Stilgenbauer S. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract. Res. Clin. Haematol. 23(1), 71-84 (2010).
20. Malek SN. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene doi:10.1038/onc.2012.411 (2012) (Epub ahead of print).
21. Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am. Soc. Hematol. Educ. Program 2011, 104-109 (2011).
22. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 22(4), 211-219 (2008).
23. Dohner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85(6), 1580-1589 (1995).
24. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370(9583), 230-239 (2007).
25. Grever MR, Lucas DM, Dewald GW et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III trial E2997. J. Clin. Oncol. 25(7), 799-804 (2007).
26. Saddler C, Ouillette P, Kujawski L et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111(3), 1584-1593 (2008).
27. Malcikova J, Smardova J, Rocnova L et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 114(26), 5307-5314 (2009).
28. Zenz T, Habe S, Denzel T et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114(13), 2589-2597 (2009).
29. Rossi D, Cerri M, Deambrogi C et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin. Cancer Res. 15(3), 995-1004 (2009).
30. Oscier D, Wade R, Davis Z et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95(10), 1705-1712 (2010).
31. Ouillette P, Collins R, Shakhan S et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 118(11), 3051-3061 (2011).
32. Gonzalez D, Martinez P, Wade R et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J. Clin. Oncol. 29(16), 2223-2229 (2011).
33. Pospisilova S, Gonzalez D, Malcikova J et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26(7), 1458-1461 (2012).
34. Oscier D, Dearden C, Erem E et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br. J. Haematol. 159(5), 541-564 (2012).
35. Skowronska A, Parker A, Ahmed G et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J. Clin. Oncol. 30(36), 4524-4532 (2012).
36. Tsimberidou AM, Tam C, Abruzzo LV et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2), 373-380 (2009).
37. Dewald GW, Brockman SR, Paternoster SF et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 121(2), 287-295 (2003).
38. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J. Clin. Oncol. 24(28), 4634-4641 (2006).
39. Oscier DG, Gardiner AC, Mould SJ et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100(4), 1177-1184 (2002).
40. Zenz T, Krober A, Scherer K et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112(8), 3322-3329 (2008).
41. Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27(24), 3994-4001 (2009).
42. Pettitt AR, Jackson R, Carruthers S et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J. Clin. Oncol. 30(14), 1647-1655 (2012).
43. Khaja R, Zhang J, Macdonald JR et al. Genome assembly comparison identifies structural variants in the human genome. Nat. Genet. 38(12), 1413-1418 (2006).
44. Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature 444(7118), 444-454 (2006).
45. Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature 463(7283), 899-905 (2010).
46. Knight SJ, Yau C, Clifford R et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 26(7), 1564-1575 (2012).
47. Edelmann J, Holzmann K, Miller F et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120(24), 4783-4794 (2012).
48. Hagenkord JM, Monzon FA, Kash SF, Lilleberg S, Xie Q, Kant JA. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. J. Mol. Diagn. 12(2), 184-196 (2010).
49. Lehmann S, Ogawa S, Raynaud SD et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 112(6), 1296-1305 (2008).
50. Zenz T, Benner A, Dohner H, Stilgenbauer S. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 7(24), 3810-3814 (2008).
51. Gunnarsson R, Staaf J, Jansson M et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 47(8), 697-711 (2008).
52. Conlin LK, Thiel BD, Bonnemann CG et al. Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis. Hum. Mol. Genet. 19(7), 1263-1275 (2010).
53. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol. Med. 15(3), 120-128 (2009).
54. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab. Invest. 87(8), 737-754 (2007).
55. Barrett MT, Scheffer A, Ben-Dor A et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc. Natl Acad. Sci. USA 101(51), 17765-17770 (2004).
56. Zhang L, Znoyko I, Costa LJ et al. Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. Cancer Genet. 204(12), 654-665 (2011).
57. Miecznikowski JC, Gaile DP, Liu S, Shepherd L, Nowak N. A new normalizing algorithm for BAC CGH arrays with quality control metrics. J. Biomed. Biotechnol. 2011, 860732 (2011).
58. Alkan C, Coe BP, Eichler EE. Genome structural variation discovery and genotyping. Nat. Rev. Genet. 12(5), 363-376 (2011).
59. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37(5), 549-554 (2005).
60. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. BioTechniques (Suppl. 56-58), 60-51 (2002).
61. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat. Rev. Genet. 14(5), 307-320 (2013).
62. Gonzalez JR, Rodriguez-Santiago B, Caceres A et al. A fast and accurate method to detect allelic genomic imbalances underlying mosaic rearrangements using SNP array data. BMC Bioinformatics 12, 166 (2011).
63. Markello TC, Carlson-Donohoe H, Sincan M et al. Sensitive quantif?ication of mosaicism using high density SNP arrays and the cumulative distribution function. Mol. Genet. Metab. 105(4), 665-671 (2012).
64. Bruno DL, Stark Z, Amor DJ et al. Extending the scope of diagnostic chromosome analysis: detection of single gene defects using high-resolution SNP microarrays. Hum. Mutat. 32(12), 1500-1506 (2011).
65. Grubor V, Krasnitz A, Troge JE et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 113(6), 1294-1303 (2009).
66. Gunn SR, Bolla AR, Barron LL et al. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk. Res. 33(9), 1276-1281 (2009).
67. Rodriguez AE, Robledo C, Garcia JL et al. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Ann. Oncol. 23(8), 2138-2146 (2012).
68. Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 111(3), 1625-1633 (2008).
69. Pfeifer D, Pantic M, Skatulla I et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109(3), 1202-1210 (2007).
70. Gunn SR, Mohammed MS, Gorre ME et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J. Mol. Diagn. 10(5), 442-451 (2008).
71. Kay NE, Eckel-Passow JE, Braggio E et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet. Cytogenet. 203(2), 161-168 (2010).
72. Van Den Neste E, Robin V, Francart J et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 21(8), 1715-1722 (2007).
73. Gunnarsson R, Mansouri L, Isaksson A et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 96(8), 1161-1169 (2011).
74. Braggio E, Kay NE, Vanwier S et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 26(7), 1698-1701 (2012).
75. Mian M, Rinaldi A, Mensah AA et al. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Ann. Oncol. 24(5), 1378-1384 (2013).
76. O'Malley DP, Giudice C, Chang AS et al. Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia. Int. J. Lab. Hematol. 33(3), 238-244 (2011).
77. Gunn SR, Hibbard MK, Ismail SH et al. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia 23(5), 1011-1017 (2009).
78. Hagenkord JM, Monzon FA, Kash SF, Lilleberg S, Xie Q, Kant JA. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. J. Mol. Diagn. 12(2), 184-196 (2010).
79. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308-311 (2001).
80. International Hapmap C. The International HapMap Project. Nature 426(6968), 789-796 (2003).
81. Iafrate AJ, Feuk L, Rivera MN et al. Detection of large-scale variation in the human genome. Nat. Genet. 36(9), 949-951 (2004).
82. Lappalainen I, Lopez J, Skipper L et al. DbVar and DGVa: public archives for genomic structural variation. Nucleic Acids Res. 41(Database issue), D936-D941 (2013).
83. Metzker ML. Sequencing technologies-the next generation. Nat. Rev. Genet. 11(1), 31-46 (2010).
84. Gargis AS, Kalman L, Berry MW et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol. 30(11), 1033-1036 (2012).
85. Clark MJ, Chen R, Lam HY et al. Performance comparison of exome DNA sequencing technologies. Nat. Biotechnol. 29(10), 908-914 (2011).
86. Bamshad MJ, Ng SB, Bigham AW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12(11), 745-755 (2011).
87. Gibson G. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13(2), 135-145 (2011).
88. Ansorge WJ. Next-generation DNA sequencing techniques. New Biotechnol. 25(4), 195-203 (2009).
89. Fabbri G, Rasi S, Rossi D et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208(7), 1389-1401 (2011).
90. Wang L, Lawrence MS, Wan Y et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365(26), 2497-2506 (2011).
91. Mansouri L, Cahill N, Gunnarsson R et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 27(2), 512-514 (2013).
92. Landau DA, Carter SL, Stojanov P et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152(4), 714-726 (2013).
93. Ellisen LW, Bird J, West DC et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66(4), 649-661 (1991).
94. Rossi D, Rasi S, Fabbri G et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119(2), 521-529 (2012).
95. Rossi D, Rasi S, Spina V et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121(8), 1403-1412 (2013).
96. Lopez C, Delgado J, Costa D et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 51(9), 881-889 (2012).
97. Quesada V, Conde L, Villamor N et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44(1), 47-52 (2012).
98. Rosati E, Sabatini R, Rampino G et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113(4), 856-865 (2009).
99. Fatima K, Paracha RZ, Qadri I. Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients. Mol. Biol. Rep. 39(5), 5059-5067 (2012).
100. Oscier DG, Rose-Zerilli MJ, Winkelmann N et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 121(3), 468-475 (2013).
101. Villamor N, Conde L, Martinez-Trillos A et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 27(5), 1100-1106 (2013).
102. Fabbri M, Urani C, Sacco MG, Procaccianti C, Gribaldo L. Whole genome analysis and microRNAs regulation in HepG2 cells exposed to cadmium. Altex 29(2), 173-182 (2012).
103. Sportoletti P, Baldoni S, Cavalli L et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br. J. Haematol. 151(4), 404-406 (2010).
104. Shedden K, Li Y, Ouillette P, Malek SN. Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia 26(5), 1108-1110 (2012).
105. Del Giudice I, Rossi D, Chiaretti S et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 97(3), 437-441 (2012).
106. Stilgenbauer S BR, Andrea Schnaiter, Paschka P et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. 53rd Annual Meeting and Exposition of the American Society of Hematology. Atlanta, GA, USA 10-13 December 2013.
107. Rosati E, Sabatini R, De Falco F et al. gamma-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int. J. Cancer 132(8), 1940-1953 (2013).
108. Visconte V, Makishima H, Jankowska A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 26(3), 542-545 (2012).
109. Schwaederle M, Ghia E, Rassenti LZ et al. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia 27(5), 1214-1217 (2013).
110. Papaemmanuil E, Cazzola M, Boultwood J et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365(15), 1384-1395 (2011).
111. Rossi D, Fangazio M, Rasi S et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119(12), 2854-2862 (2012).
112. Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119(18), 4101-4107 (2012).
113. Stilgenbauer S, Liebisch P, James MR et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 93(21), 11837-11841 (1996).
114. Kanduri M, Tobin G, Aleskog A, Nilsson K, Rosenquist R. The novel NF-kappaB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia. Blood Cancer J. 1(3), e12 (2011).
115. Hertlein E, Wagner AJ, Jones J et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 116(1), 45-53 (2010).
116. Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012).
117. Keats JJ, Chesi M, Egan JB et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120(5), 1067-1076 (2012).
118. Walter MJ, Shen D, Ding L et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366(12), 1090-1098 (2012).
119. Mamanova L, Coffey AJ, Scott CE et al. Target-enrichment strategies for next-generation sequencing. Nat. Methods 7(2), 111-118 (2010).
120. Domenech E, Gomez-Lopez G, Gzlez-Pena D et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PloS ONE 7(6), e38158 (2012).
121. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6), 1175-1184 (2012).